Expressions and significance of tumor suppressor gene PTEN and p53 in prostate cancer.

被引：0

作者：

Lu, Wei ^{[1
]}

Wang, Jia-Qiang ^{[1
]}

Zhang, Yu-Hong ^{[1
]}

Wang, Yong ^{[1
]}

Yin, Wen-Jing ^{[1
]}

Guo, Jian-Min ^{[1
]}

Li, Yi ^{[1
]}

Wang, Yan-Min ^{[1
]}

Lian, Ji-Hu ^{[1
]}

Gao, Ying-Yuan ^{[1
]}

Wang, Xiao-Ran ^{[1
]}

Liu, Bing-Chen ^{[1
]}

机构：

[1] Jilin Prov Peoples Hosp, Dept Urol, Changchun, Jilin, Peoples R China

来源：

BIOMEDICAL RESEARCH-INDIA | 2017年 / 28卷 / 15期

关键词：

Prostate cancer; p53; (Phosphatase and tensin homolog) PTEN; Immunohistochemistry; PROTEIN EXPRESSION; GROWTH; CELLS;

D O I：

暂无

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

The study aim was to investigate the impacts of the expressions of tumor suppressor gene phosphatase and tensin homolog deleted on chromosome ten (PTEN) and p53 on the grading and prognosis of prostate cancer. Immunohistochemistry was used to detect the expressions of tumor suppressor gene PTEN and p53 in 80 prostate cancer and adjacent tissue samples, as well as in 40 normal tissue samples, and the relationships among their expressions, prostate cancer grading, and prognosis were then compared. p53 was significantly up-regulated in prostate cancer tissue (P<0.05), but PTEN was significantly down-regulated (P<0.05). The expression levels of PTEN in the cancer tissues with different differentiation degrees, stages, metastasis, and prognosis exhibited significant differences (P<0.05). The expression levels of p53 in the cancer tissues with different differentiation degrees and prognosis exhibited significant differences (P<0.05). There were no correlations between the expressions of p53 and PTEN (P>0.05). Apoptosis-related gene p53 and PTEN participate in the grading of prostate cancer, and also affect patient's prognosis, but there are no correlations between these two genes.

引用

页码：6730 / 6734

页数：5

共 25 条

[1] Early Detection of Prostate Cancer: AUA Guideline
Carter, H. Ballentine
Albertsen, Peter C.
Barry, Michael J.
Etzioni, Ruth
Freedland, Stephen J.
Greene, Kirsten Lynn
Holmberg, Lars
Kantoff, Philip
Konety, Badrinath R.
Murad, Mohammad Hassan
Penson, David F.
Zietman, Anthony L.
[J]. JOURNAL OF UROLOGY, 2013, 190 (02) : 419 - 426
[2] Benign prostatic hyperplasia and prostate cancer
Guess, HA
[J]. EPIDEMIOLOGIC REVIEWS, 2001, 23 (01) : 152 - 158
[3] Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas
He, Dan
Zhang, Yi-wang
Zhang, Na-na
Zhou, Lu
Chen, Jian-ning
Jiang, Ye
Shao, Chun-kui
[J]. MEDICAL ONCOLOGY, 2015, 32 (04) : 1 - 16
[4] Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Hong, Bo
van den Heuvel, A. Pieter J.
Prabhu, Varun V.
Zhang, Shengliang
El-Deiry, Wafik S.
[J]. CURRENT DRUG TARGETS, 2014, 15 (01) : 80 - 89
[5] Expression of WWOX and FHIT is downregulated by exposure to arsenite in human uroepithelial cells
Huang, Ya-Chun
Hung, Wen-Chun
Chen, Wan-Tzu
Yu, Hsin-Su
Chai, Chee-Yin
[J]. TOXICOLOGY LETTERS, 2013, 220 (02) : 118 - 125
[6] A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53
Kim, J.
Roh, M.
Doubinskaia, I.
Algarroba, G. N.
Eltoum, I-E A.
Abdulkadir, S. A.
[J]. ONCOGENE, 2012, 31 (03) : 322 - 332
[7] p53 mutations in cancer
Muller, Patricia A. J.
Vousden, Karen H.
[J]. NATURE CELL BIOLOGY, 2013, 15 (01) : 2 - 8
[8] Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers
Nakahata, Shingo
Ichikawa, Tomonaga
Maneesaay, Phudit
Saito, Yusuke
Nagai, Kentaro
Tamura, Tomohiro
Manachai, Nawin
Yamakawa, Norio
Hamasaki, Makoto
Kitabayashi, Issay
Arai, Yasuhito
Kanai, Yae
Taki, Tomohiko
Abe, Takaya
Kiyonari, Hiroshi
Shimoda, Kazuya
Ohshima, Koichi
Horii, Akira
Shima, Hiroshi
Taniwaki, Masafumi
Yamaguchi, Ryoji
Morishita, Kazuhiro
[J]. NATURE COMMUNICATIONS, 2014, 5 : 3393
[9] Nakamura T, 2003, HEPATO-GASTROENTEROL, V50, P1321
[10] Nesslinger NJ, 2003, CANCER RES, V63, P2228

← 1 2 3 →